Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Innovative Food Holdings delays Q1 2026 report filing to May 20 due to audit and staffing issues

Market News
08 May 2026
GlobeNewsWire
View Source
Neutral
pluang ai news

Innovative Food Holdings, a gourmet specialty foods seller, announced it will file its Q1 2026 report by May 20, 2026, later than usual due to delays in completing its audit and interim review. The delay stems from timing needed to finalize fiscal 2026 audit work and recent staffing changes in finance, which extended the internal review process. The company plans to hold its Q1 2026 investor call after the report filing and its annual meeting on May 19. This update informs investors about the adjusted reporting timeline and upcoming investor communication.

More News

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Adventure & Dive Resort in Belize was ranked the #1 hotel in Central America and #15 globally in the 2026 Tripadvisor Travelers’ Choice Best of the Best Awards. This prestigious recognition is based on exceptional guest reviews and highlight...

Others
Neutral
1 hour ago
US government buys 10% stake in mining firms, signaling a new strategic investment trend.

US government buys 10% stake in mining firms, signaling a new strategic investment trend.

In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

Market News
Bullish
1 hour ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

Market News
Bullish
2 hours ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...

Market News
Bullish
2 hours ago
Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express, Inc. announced a regular quarterly cash dividend of $0.02 per share, payable on July 6, 2026, to shareholders of record as of June 23, 2026. This marks the company's 92nd consecutive quarterly dividend, with a total payout of $564....

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App